Journal
NEUROLOGY
Volume 61, Issue 2, Pages 206-211Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/01.WNL.0000073987.79060.4B
Keywords
-
Categories
Funding
- NIA NIH HHS [AG5131] Funding Source: Medline
- PHS HHS [10869, 18440] Funding Source: Medline
Ask authors/readers for more resources
Background: The neurodegenerative process in Alzheimer's disease (AD) and in the Lewy body variant of AD (LBV) patients is characterized by cholinergic dysfunction and deposition of amyloid beta-peptide (Abeta) 1-40 and 1-42; however, the differential effects of Abeta species on the cholinergic system are not completely clear. Objective: To better understand the relationship between levels of Abeta 1-40 and 1-42 on cholinergic deficits in AD and LBV patients. Methods: Levels of choline acetyltransferase (ChAT) activity and ChAT immunoreactivity in the plaques in the frontal cortex of patients with AD and LBV were correlated with Abeta1-42 and 1-40 levels determined by ELISA and with neuropathologic and neurologic markers. Results: Although the overall levels of ChAT activity were reduced in AD and LBV cases, there was a direct correlation with Abeta1-42 levels. Furthermore, patients with high Abeta1-42 levels had more abundant cholinergic dystrophic neurites in the plaques than cases with lower Abeta1-42. Conclusion: Abeta1-42 may also trigger cholinergic dysfunction by promoting aberrant neuritic sprouting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available